Shares of Amanta Healthcare made a muted debut on Tuesday, listing at a 7% premium over the IPO price of ₹126. On the NSE, the stock opened at ₹135 per share, while on the BSE it was listed at ₹134, valuing the company at ₹520.31 crore post-listing.
The debut was broadly in line with grey market premium (GMP) trends, which indicated a steady premium of around ₹9, or 7.14%, over the upper end of the price band.
IPO subscription details
The ₹126 crore IPO, which ran from September 1–3, received an overwhelming response, with an overall subscription of 82.61 times:
-
NIIs: 209.42 times
-
Retail: 54.98 times
-
QIBs: 35.86 times
Ahead of the issue, Amanta raised ₹37.8 crore via the anchor book from six institutional investors.
Use of proceeds
At a post-issue valuation of nearly ₹500 crore, the Ahmedabad-based pharma company plans to deploy:
-
₹70 crore for expanding its SteriPort manufacturing line
-
₹30.1 crore for a new Small Volume Parenterals (SVP) line
-
The rest towards general corporate purposes
Company profile & financials
Founded in 1994, Amanta Healthcare manufactures sterile liquid pharmaceuticals and medical devices, leveraging Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.
It has over 320 domestic distributors and a strong export presence across Africa, Latin America, the UK, and other emerging markets.
For FY25, Amanta reported consolidated revenue of ₹274.7 crore versus ₹280.3 crore in FY24. Profitability improved sharply, with PAT rising to ₹10.5 crore in FY25 compared to ₹3.6 crore in FY24.
